Jefferies Initiates Coverage of City Therapeutics with Buy Rating
Jefferies analyst Maury Raycroft initiated coverage on City Therapeutics with a buy rating and a $32 price target.
Stocks · News reference
City Therapeutics Doses First Participant in Phase 1 Clinical Trial of CITY-RBP4
City Therapeutics has initiated its Phase 1 clinical trial for CITY-RBP4, an RNAi therapeutic candidate for Stargardt disease, by dosing the first participant.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Oppenheimer Initiates Coverage of City Therapeutics with Outperform Rating
Oppenheimer has initiated coverage of City Therapeutics with an Outperform rating and a $46 price target.
Jefferies Initiates Coverage On City Therapeutics with Buy Rating, Announces Price Target of $32
This MongoDB Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Analysts initiated coverage on Mentari, MongoDB, Comfort Systems and Ross Stores; City Therapeutics received an early-stage biotech rating.
Oppenheimer Initiates Coverage On City Therapeutics with Outperform Rating, Announces Price Target of $46
8-K filing — CITY THERAPEUTICS, INC. (CTY)
Filed: 2026-11-10 AccNo: 0001104659-26-124775 Size: 215 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits